Algernon Health Inc (AGN) Videos/Articles https://www.algernonhealth.com/news-media/videos-articles/rss en-us https://d1io3yog0oux5.cloudfront.net/_2650428c475a29eb8fac4af4b79a827f/algernonpharmaceuticals/files/theme/images/logo-sm_2x.png Algernon Health Inc Logo https://www.algernonhealth.com Equisolve Investor Relations Suite <![CDATA[Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI]]> https://www.bnnbloomberg.ca/investment-trends/2024/12/16/algernon-ceo-discusses-ifenprodil-sale-to-seyltx-and-dmt-as-a-treatment-for-stroke-and-tbi/ Mon, 16 Dec 24 00:00:00 -0500 https://www.bnnbloomberg.ca/investment-trends/2024/12/16/algernon-ceo-discusses-ifenprodil-sale-to-seyltx-and-dmt-as-a-treatment-for-stroke-and-tbi/ <![CDATA[How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment]]> https://www.bnnbloomberg.ca/investment-trends/2024/12/10/how-algernon-pharmaceuticals-is-unlocking-sub-psychedelic-dmt-for-stroke-and-tbi-treatment/ Mon, 09 Dec 24 00:00:00 -0500 https://www.bnnbloomberg.ca/investment-trends/2024/12/10/how-algernon-pharmaceuticals-is-unlocking-sub-psychedelic-dmt-for-stroke-and-tbi-treatment/ <![CDATA[The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22265/the-dales-report-why-psychedelic-treatments-will Mon, 27 Feb 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22265/the-dales-report-why-psychedelic-treatments-will <![CDATA[Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22264/radius-research-interview-algernon-neuroscience Wed, 22 Feb 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22264/radius-research-interview-algernon-neuroscience <![CDATA[Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22263/proactive-investors-ceo-interview-algernon-neuroscience Thu, 16 Feb 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22263/proactive-investors-ceo-interview-algernon-neuroscience <![CDATA[SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22262/sr-times-drug-could-possibly-both-reduce-acute Tue, 07 Feb 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22262/sr-times-drug-could-possibly-both-reduce-acute <![CDATA[Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22261/radius-research-interview-algernon-pharmaceuticals Mon, 30 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22261/radius-research-interview-algernon-pharmaceuticals <![CDATA[Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22260/radius-research-algernon-pharma-agn-ceo-chris-moreau Sat, 21 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22260/radius-research-algernon-pharma-agn-ceo-chris-moreau <![CDATA[Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22259/benzinga-a-psychedelic-program-for-treatment-of-stroke Wed, 18 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22259/benzinga-a-psychedelic-program-for-treatment-of-stroke <![CDATA[Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22258/microdose-microdosing-dmt-to-treat-stokes-not-as-trippy Tue, 17 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22258/microdose-microdosing-dmt-to-treat-stokes-not-as-trippy <![CDATA[Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22257/proactive-investors-ceo-interview-algernon-neuroscience Tue, 17 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22257/proactive-investors-ceo-interview-algernon-neuroscience <![CDATA[The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22256/the-market-herald-algernon-pharmaceuticals-announces Tue, 10 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22256/the-market-herald-algernon-pharmaceuticals-announces <![CDATA[Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22255/proactive-investors-interview-algernon-pharmaceuticals Mon, 09 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22255/proactive-investors-interview-algernon-pharmaceuticals <![CDATA[Benzinga – Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22254/benzinga-psychedelic-subsidiaries-news-blackhawk-spins Wed, 04 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22254/benzinga-psychedelic-subsidiaries-news-blackhawk-spins <![CDATA[Proactive Investors Interview – Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22253/proactive-investors-interview-algernon-pharmaceuticals Wed, 04 Jan 23 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22253/proactive-investors-interview-algernon-pharmaceuticals <![CDATA[Wonderland 2022 Recap: Algernon Pharmaceuticals]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22252/wonderland-2022-recap-algernon-pharmaceuticals Fri, 02 Dec 22 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22252/wonderland-2022-recap-algernon-pharmaceuticals <![CDATA[The National Investor – Repurposing Drugs For New Needs — Algernon Pharmaceuticals Inc. (CSE-AGN; OTCQB-AGNPF)]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22251/the-national-investor-repurposing-drugs-for-new-needs Wed, 30 Nov 22 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22251/the-national-investor-repurposing-drugs-for-new-needs <![CDATA[Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon for Algernon Pharmaceuticals DMT Study]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22250/psychedelic-therapeutics-for-human-stroke-participant Mon, 21 Nov 22 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22250/psychedelic-therapeutics-for-human-stroke-participant <![CDATA[MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22249/marketone-video-interview-with-ceo-christopher-j-moreau Thu, 17 Nov 22 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22249/marketone-video-interview-with-ceo-christopher-j-moreau <![CDATA[Psychedelic Finance – Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22248/psychedelic-finance-feature-christopher-j-moreau Wed, 16 Nov 22 00:00:00 -0500 https://www.algernonhealth.com/news-media/videos-articles/detail/22248/psychedelic-finance-feature-christopher-j-moreau <![CDATA[Drug Discovery and Development – Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22247/drug-discovery-and-development-why-algernon-believes-it Fri, 04 Nov 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22247/drug-discovery-and-development-why-algernon-believes-it <![CDATA[Psychedelic Finance – Feature: Algernon Pharmaceuticals]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22246/psychedelic-finance-feature-algernon-pharmaceuticals Thu, 03 Nov 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22246/psychedelic-finance-feature-algernon-pharmaceuticals <![CDATA[Market One – Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 Study of DMT for Stroke]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22245/market-one-algernon-pharmaceuticals-receives-approval Thu, 03 Nov 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22245/market-one-algernon-pharmaceuticals-receives-approval <![CDATA[Born2Invest – Algernon Pharmaceuticals Is Developing Pioneering Treatments With a Cost-Efficient R&D Pipeline]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22244/born2invest-algernon-pharmaceuticals-is-developing Fri, 28 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22244/born2invest-algernon-pharmaceuticals-is-developing <![CDATA[BNN Bloomberg – In a sector ripe for revival, Algernon’s development pipeline positions it well.]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22243/bnn-bloomberg-in-a-sector-ripe-for-revival Wed, 26 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22243/bnn-bloomberg-in-a-sector-ripe-for-revival <![CDATA[Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Yale Clinical Trial for DMT Phase 2 Depression Study]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22242/radius-research-algernon-pharmaceuticals-agn-ceo Tue, 25 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22242/radius-research-algernon-pharmaceuticals-agn-ceo <![CDATA[Psychedelic Spotlight – Prolonged DMT Infusions could be a Breakthrough for Stroke Patients]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22241/psychedelic-spotlight-prolonged-dmt-infusions-could-be Mon, 10 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22241/psychedelic-spotlight-prolonged-dmt-infusions-could-be <![CDATA[Drug Discovery and Development – DMT pioneer Rick Strassman weighs in on psychedelic hope and hype]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22240/drug-discovery-and-development-dmt-pioneer-rick Thu, 06 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22240/drug-discovery-and-development-dmt-pioneer-rick <![CDATA[High TImes – New Research Exploring DMT as a Treatment for Stroke]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22239/high-times-new-research-exploring-dmt-as-a-treatment Wed, 05 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22239/high-times-new-research-exploring-dmt-as-a-treatment <![CDATA[Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Business Update – Ifenprodil & DMT Trials]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22238/radius-research-algernon-pharmaceuticals-agn-ceo Mon, 03 Oct 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22238/radius-research-algernon-pharmaceuticals-agn-ceo <![CDATA[Mugglehead Magazine – Algernon receives approval to conduct DMT study in the Netherlands]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22237/mugglehead-magazine-algernon-receives-approval-to Mon, 26 Sep 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22237/mugglehead-magazine-algernon-receives-approval-to <![CDATA[Pulmonary Fibrosis News – Orphan Drug Status Sought for NP-120 to Treat IPF With Cough]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22236/pulmonary-fibrosis-news-orphan-drug-status-sought-for Sat, 24 Sep 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22236/pulmonary-fibrosis-news-orphan-drug-status-sought-for <![CDATA[Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22235/proactive-investors-interview-algernon-pharmaceuticals Mon, 12 Sep 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22235/proactive-investors-interview-algernon-pharmaceuticals <![CDATA[Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22234/streetwise-reports-will-pharma-co-keep-pushing-higher Mon, 05 Sep 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22234/streetwise-reports-will-pharma-co-keep-pushing-higher <![CDATA[Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22233/proactive-investors-interview-algernon-pharmaceuticals Thu, 01 Sep 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22233/proactive-investors-interview-algernon-pharmaceuticals <![CDATA[Streetwise Reports – Hedge Fund Doubles Position in Biotech Co.]]> https://www.algernonhealth.com/news-media/videos-articles/detail/22232/streetwise-reports-hedge-fund-doubles-position-in Tue, 23 Aug 22 00:00:00 -0400 https://www.algernonhealth.com/news-media/videos-articles/detail/22232/streetwise-reports-hedge-fund-doubles-position-in